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Introduction
Prolyl hydroxylase domain protein 2 (PHD2) is the primary regulator of steady-state levels of the transcription factor hypoxiainducible factor 1a (HIF1a) (Bruick, 2001; Harten et al., 2010; Miyata et al., 2010; Fong and Takeda, 2008; Nagel et al., 2010) . HIF1a is itself responsible for up-regulating the expression of genes involved in response to hypoxia and other forms of cellular stress (Siddiq et al., 2005; Greer et al., 2012; Nakayama, 2009) . HIF1a is marked for the proteasome degradation pathway through hydroxylation of proline-564 and proline-402 by PHD2. Prolyl hydroxylation is critical for promoting binding of HIF1a to the Von Hippel Lindau (VHL) E3 ligase, resulting in its polyubiquitination and subsequent proteasomal degradation. We previously reported that PHD inhibition in the context of either acute or chronic in vivo mouse models of PD resulted in protection of vulnerable DAergic SNpc neurons via increases in HIF1a levels (Lee et al., 2009; Rajagopalan et al., 2014 Rajagopalan et al., , 2016 . Levels of PHD2 have been reported to be elevated within affected human PD SNpc tissues in conjunction with reduced levels of HIF1a, suggesting that chronically elevated levels of PHD2 may contribute to neurodegenerative events associated with the disorder (Mandel et al., 2008; Grenblatt et al., 2004; Elstner et al., 2011; Rajagopalan et al., 2016) .
Hsp90 inhibition has been widely studied as a potential therapeutic target for PD, largely in the context of its ability to enhance hsp70 induction in response to alpha-synuclein neurotoxicity or mitochondrial stress. Hsp70 overexpression has been shown to suppress alpha-synuclein aggregation and neurotoxicity in various synucleinopathy models as well as neurodegeneration associated with the mitochondrial neurotoxins rotenone and 1-methyl-4-phenyl-2,3,6-tetrahydropyridine (MPTP) (Zhou and Freed, 2003; Klucken et al., 2004; McLean et al., 2004; Cantuti-Castelvetri et al., 2005; Shin et al., 2005; Flower et al., 2005; Falsone et al., 2009; Chaari et al., 2013) . There are conflicting reports, however, which demonstrate that induction of hsp70 alone is not sufficient to prevent alpha-synuclein or MPTP-mediated neurotoxicity in vivo (Shimshek et al., 2010; Li et al., 2012) . This suggests that the hsp90 chaperone complex may play alternative roles in these neurodegenerative PD-associated phenotypes.
PHD2 has recently been reported to be capable of interacting with the hsp90 co-chaperone p23, resulting in its recruitment and stabilization by the hsp90 chaperone complex (Song et al., 2013 (Song et al., , 2014 . Here we report that under conditions of mitochondrial stress elicited by the MPTP metabolite MPP + , PHD2 becomes associated with the hsp90-p23 chaperone complex within cultured DAergic cells. In these same cells, p23 knockdown results in select reductions in steady-state levels of the PHD2 isoform corresponding with its increased activation and protection against MPP + -mediated neurotoxicity. Administration of the p23 inhibitor gedunin also elicits neuroprotection against MPP + in these cells as well as in human iPSC-derived neurons. We propose that p23 via its ability to initiate chaperone-mediated PHD2 stabilization may contribute to mitochondrial stress-related events associated with PD. This suggests a novel connection between two pathways previously independently associated with PD neuropathology via the hsp90 co-factor p23.
Materials and methods

Experimental procedures
2.1.1. Cells and treatments N27 cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin and incubated at 37o C with 5% CO 2 . Cells were treated with 500 mM
MPP
+ for 24 h prior to processing of cell lysates for immunoprecipitation (IP), western blotting or cell viability analyses. Human iPSC-derived DAergic neurons were purchased from XCell Science Inc. where they were subject strict quality control analyses including dopaminergic differentiation per the manufacturer's specifications. Cells were treated with different concentrations of MPP + (0.5-1 mM) for 24 h prior to analysis of cell viability. For gedunin experiments, N27 and iPSC-derived neurons were pretreated with 1 mM and 5 mM concentrations of the drug respectively, 1 h prior to addition of 500 mM MPP + .
2.1.2. PHD2 IP N27 cells were grown to confluency on 10 cm plates followed by growth in either 500 mM MPP + or vehicle for 24 h. Cell pellets were collected following centrifugation at 500 Â g for 2 min followed by lysis in RIPA buffer (20 mMTris/HCl, pH 7.8, 50 mMKCl, 2 mM DTT, 0.1% Nonidet P-40, 10 mMNaF, 1 mM NaVO 4 , 2 mM b-glycerophosphate, 2 mM sodium pyrophosphate) supplemented with a protease inhibitor mixture (Roche Applied Science). Immunoprecipitation was carried out by treating 500 mg of cell lysate with protein A immobilized on cross-linked 4% beaded agarose (Sigma, P2545) to remove endogenous immunoglobulins, followed by incubation with PHD2 primary antibody (Cell Signaling), and precipitation with protein A macrobeads (Sigma, P6486) in 20 mM phosphate buffered saline (pH 7.0; PBS) overnight at 4 C. The protein-antibody complex was washed three times with cold PBS and then boiled with SDS-PAGE sample buffer to extract the antigenic proteins for SDS-PAGE separation. Protein complexes were resolved on SDS-PAGE (10% gel) and analyzed by Western blotting (see below).
Knockdown of p23 in DAergic cells
N27 cells were transfected with various concentrations (0-80 nM) of p23 siRNA (Eurofins) versus scrambled control via Lipofectamine 3000 reagent (Invitrogen). Transfection efficiency and reductions in p23 levels were verified by western blot analysis using p23 antibodies.
Nuclear sub-fractionation
Nuclear fractions were obtained from different treatment groups using NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Scientific) as per manufacturer's instructions. Briefly, the cell pellet was obtained by centrifugation at 500 Â g for 5 min. The pellet was resuspended in reagents CER I followed by CER II, vortexed and centrifuged to get cytoplasmic fraction in the supernatant. The pellet was vortexed with NER reagent for 15 s over a period of 40 min. Nuclear fraction was obtained in the supernatant after centrifuging at 16,000 Â g for 10 min.
Western blotting
Cellular lysates were homogenized in buffer containing 50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.25% sodium deoxycholate, and 1 mM EDTA followed by centrifugation at 10,000 Â g for 10 min. Supernatant was taken and protein concentration estimated via the Bradford assay. Aliquots of 25 ug protein were boiled at 95 C in Lamelli buffer for 5 min and loaded onto a 10% SDS-PAGE gel. Following electrophoresis, bands were transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were next incubated in primary antibodies (PHD1, 1:1000 dilution, Novus; PHD2, 1:1000 dilution, Cell Signaling; PHD3, 1:1000 dilution, Novus; p23, 1:1000, BD Biosciences; hsp90, 1:1000, Cell Signaling Technologies; HIF1a, 1:500, Novus; Hsp70, 1:1000, Cell Signaling; ßactin, 1:5000 dilution, Millipore) for 24 h, 4 C. This was followed by incubation in appropriate HRP-conjugated secondary antibodies for 1 h at RT. Immunoblots were developed using Enhanced Chemiluminescence (ECL) reagent and analyzed using a ChemDoc system from BioRad.
HIF1a immunocytochemistry
Cells were fixed with 4% paraformaldehyde and processed for immunocytochemistry to determine nuclear translocation of HIF1a. Briefly, fixed cells were incubated in primary HIF1a antibody (1:200, Novus) overnight at 4 C followed by Alexa-conjugated secondary antibody. Images were captured on a Zeiss LSM 510 confocal microscope for quantitation.
Quantitative real-time RT-PCR
A pure RNA tissue kit (Roche) was used to isolate RNA and HIF1a expression determined via qPCR using SYBR Green master mix (Roche). The primer sets used were as follows:
HIF1a forward: 5 0 -AAG CAC TAG ACA AAG CTC ACC -3 0 ; HIF1a reverse: 5 0 -TTG ACC ATA TCG CTG TCC AC -3 0 . Data were normalized to ßactin.
Cell viability
Cell viability was assessed via the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) assay and the Abcam cell proliferation assay.
2.1.9. HPLC to assess cellular MPP + uptake
Cell pellet was sonicated in 300 mL of 0.1 M perchloric acid (PCA), and a 20 mL of sonicated lysate was collected in a chilled 1.5 ml vials for protein content determination. The remaining sonicated samples were centrifuged at 14,000 rpm for 20 min at 4 C and the supernatant collected was again centrifuged with same parameters. The supernatant were diluted and an aliquot of the diluted supernatant was injected onto a terra MS C18 5 uM (4.6 Â 250 mm) column (W22071K019, Waters). Samples were eluted isocratically with the mobile phase that composed of 20 mM boric acid-sodium borate buffer, pH 7.75, containing 3 mM tetrabutylammonium hydrogen sulfate, 0.25 mM 1-heptanesulfonic acid, and 10% isopropanol. The fluorescence detector set for excitation at 295 nm and emission at 375 nm was used to detect MPP+ levels Kaidery et al., 2013) . Concentrations of MPP+ were expressed as nanograms per milligrams tissue weight.
Statistics
Results are presented as means AE SEM. Two-way Anova followed by Tukey's multiple comparison test were performed to analyze statistical significance of in vivo data and one-way Anova followed by Tukey's multiple comparison for in vitro N27 studies and in human iPSC-derived neurons, all run using PRISM software. A value of p < 0.05 was considered significant. PHD2 inhibition results in reductions in DAergic neurodegeneration in both acute and age-related chronic in vivo models of PD-associated mitochondrial stress (Lee et al., 2009; Rajagopalan et al., 2014 Rajagopalan et al., , 2016 . Alleles of PHD2 present in the human genome residing within its coding region have recently been linked to reduced binding of the protein to the p23 cochaperone, preventing PHD2 0 s subsequent recruitment and stabilization by hsp90 and reduced ability to down-regulate HIF1a signaling (Song et al., 2014) . This suggested to us that p23 could serve as a potential link between the hsp90 and PHD2-HIF1a pathways under conditions of mitochondrial DAergic stress associated with PD.
We first tested whether interactions between PHD2 and the hsp90-p23 complex were increased in the context of a published DAergic cell model of mitochondrial stress in which neurotoxicity is prevented by PHD2 inhibition involving the treatment of cultured rat DAergic N27 cells with the mitochondrial neurotoxin MPP + (Lee et al., 2009 ). Administration of MPP + was found to result in increased levels of both p23 and hsp90 which coimmunoprecipitated with the PHD2 protein (Fig. 1 ). This suggests that under conditions of PD-related mitochondrial stress, there is an increased association between PHD2 and the p23-hsp90 chaperone complex that could impact on PHD stability and subsequent function.
Genetic knockdown of p23 levels in DAergic cells results in selective reductions in PHD2 protein and activity levels
PHD2 contains a highly conserved zinc finger domain that has recently been reported to interact with a binding motif within p23, allowing its recruitment to and stabilization by hsp90 (Song et al., 2014) . We noted that this domain was absent in other known PHD isoforms. We hypothesized that reductions in p23 levels in our DAergic cell model should therefore selectively interfere with the stability of PHD2 protein levels. Selective knockdown of p23 was found to result in a dose-dependent reduction in steady-state PHD2 protein levels ( Fig. 2A and B) . This did not however impact on protein levels of other known PHD isoforms (PHD1 and PHD3) at dosages that elicited effects on PHD2 levels (Fig. 2C) . Knockdown in p23 eliciting select reductions in PHD2 protein levels in turn corresponded with reduced PHD2 activity as indicated by increases in nuclear HIF1a translocation (Fig. 2D, E) . We verified that this was independent of induction of HIF1a gene expression via qPCR in p23 knockdown cells versus scrambled controls (Fig. 2F) 3.3. Genetic p23 knockdown in DAergic N27 cells prevents MPP + -mediated neurotoxicity Next we asked whether genetic knockdown of p23 in DAergic cells could prevent neurotoxicity mediated by MPP + treatment. In comparison to scrambled controls, expression of p23-specific siRNA which resulted in significant reductions in its levels as well as those of PHD2 was found to prevent DAergic cell loss associated with MPP + administration (Fig. 3A) . To verify that this was not due to inductions in Hsp70 levels, we performed western blot analyses in p23 knockdown versus control cells (Fig. 3B,C) . Knockdown of p23 in DAergic N27 cells did not alter HSP70 levels, indicating that the neuroprotective effects are independent of HSP70 induction.
Inhibition of p23 activity via gedunin prevents MPP + -mediated neurotoxicity in both DAergic N27 cells and in human iPSC-derived neurons
The miscible flavone compound gedunin has been demonstrated to act via direct interaction with p23, preventing it from binding to hsp90. In this manner, gedunin acts as a select inhibitor of hsp90 chaperone activity without interfering with the activities of other Hsp90 co-chaperones (Patwardhan et al., 2013) . Gedunin treatment of DAergic N27 cells did not impact on MPP + uptake by the cells and was found to significantly attenuate MPP + -mediated cell loss (Fig. 4A, B) . It was also attenuated cell loss associated with MPP + treatment of human iPSC-derived DAergic neurons (Fig. 4C) . 
Discussion
The hsp90 chaperone complex has been widely reported to be associated with PD and its inhibition to protect against neurodegenerative phenotypes in a variety of disease models (Uryu et al., 2006; Falsone et al., 2009 ). Hsp90 inhibitors are largely believed to elicit their effects via induction of hsp70, although hsp70 induction alone is not neuroprotective in all models of PD including following systemic administration of MPTP Klucken et al., 2004; Cantuti-Castelvetri et al., 2005) . This suggests that the hsp90 chaperone complex may play additional roles in neurodegenerative phenotypes associated with PD.
PHD2 levels have been demonstrate (Elstner et al., 2011 ) elevated within affected DAergic neurons in post-mortem SNpc tissues isolated from PD patients versus age-matched controls, in conjunction with reduced HIF1a levels (Mandel et al., 2008; Grenblatt et al., 2004; Elstner et al., 2011) . We previously reported that PHD inhibition acting via inductions in HIF1a signaling results in significant neuroprotection of vulnerable DAergic SNpc neurons in both acute and chronic in vivo mouse models of the disease (Lee et al., 2009; Rajagopalan et al., 2014 Rajagopalan et al., , 2016 . This was found to be associated with reductions in levels of mitochondrial dysfunction in these models (Lee et al., 2009; Rajagopalan et al., 2014) . PHD inhibitors have also been implicated as therapeutics for neuroprotection within the central nervous system in association with other conditions including stroke and ischemic injury and in chronic models of both Alzheimer's and Huntington's disease (Uryu et al., 2006; Natarajan et al., 2009; Siddiq et al., 2007 Siddiq et al., , 2009 Siddiq, 2008; Niatsetskaya et al., 2010; Kant et al., 2013; de Lemos et al., 2013) . PHD inhibitors are however broad-acting and may have effects on other PHD isoforms.
The p23 protein has recently been reported to specifically recruit PHD2 protein to the Hsp90 chaperone complex via select binding to a zinc finger domain that is found only within the PHD2 isoform (Song et al., 2013) . Human PHD2 alleles within the zinc finger binding site are associated with reduced p23 binding and decreased PHD2 protein stabilization by the hsp90 chaperone complex (Song et al., 2014) . Our current data demonstrates that mitochondrial stress elicited by the mitochondrial neurotoxin MPP + result in elevated levels of PHD2 protein in cultured DAergic N27 cells in conjunction with increased interaction with the hsp90-p23 chaperone complex. Genetic p23 knockdown in these cells was found to selectively reduce PHD2 protein levels and subsequent activity resulting in increased HIF1a activity and prevention of MPP + -mediated neurotoxicity in a manner independent of Hsp70 induction. This is in keeping with previous data from our laboratory where we demonstrated that over-expression of wildtype p23 in N27 cells resulted in increased sensitivity to the neurotoxic effects of paraquat which was reduced in cells expressing mutant p23 (Chinta et al., 2008) . Neuronal expression of wildtype p23 in vivo has been reported to result in neurological defects that track with p23 expression levels (Gong et al., 2011) .
The p23 inhibitor gedunin was also found to protect against neurotoxicity associated with MPP + in DAergic N27 cells. The ability to reiterate these results in iPSC-derived neurons suggests that our findings are relevant in a non-transformed human cell model of the disease. Based on these data, we propose that hsp90 may elicit toxic effects on DAergic neurons in the face of mitochondrial stress via interaction with p23 that acts to recruit PHD2 to the hsp90 complex resulting in stabilization of the PHD2 protein. This in turn results in reductions in neuroprotective HIF1a levels. HIF1a knockdown both in murine midbrain-derived neural precursor cells (NPCs) and in DAergic SN neurons in vivo has been reported to result in neuronal cell loss, suggesting that maintenance of HIF1a levels are important for survival of these cells (Milosevic et al., 2007; Lin et al., 2014) . Small molecule inhibitors of hsp90 such as geldanamycin that act by binding the ATP pocket of the protein have been demonstrated to prevent neurotoxicity associated with various PD mouse models, including following in vivo MPTP administration (Shimshek et al., 2010; Li et al., 2012) . Though results in animal models have been promising, clinical utility of these inhibitors have to date been limited by poor solubility, blood-brain-barrier penetration, toxicity issues, or failure to protect against frank loss of nigrostriatal DAergic neurons (McFarland et al., 2014) . The miscible flavone compound gedunin directly binds to p23 and prevents its interaction with hsp90, thereby inhibiting hsp90 chaperone activity without interfering with the activities of any of the other $20 known Hsp90 co-chaperones (Patwardhan et al., 2013) . Gedunin is a natural product isolated from the Meliacae family of medicinal plants and has been extensively used for treatment of malaria and other infectious diseases in the context of traditional Indian medicine. Gedunin or its derivatives including 7-oxo-gedunin could provide a novel alternative for use in the treatment of PD that may have less broad effects than other hsp90 inhibitors that have been explored to date (Patwardhan et al., 2013) . The gedunin derivative deosygedunin has indeed previously been reported to be neuroprotective against in vivo MPTP neurotoxicity (although not confirmed using stereological cell counts) (Nie et al., 2015) . Neuroprotection was found to correlate with modest increases in the activation of TrkB receptors within the SNpc, although definitive proof of trkB activation as the direct cause of drug-mediated neuroprotection (e.g. by its genetic knockdown) was not pursued in these studies (Nie et al., 2015) . This could however still constitutes an alternative or additional explanation for the neuroprotective effects elicited by gedunin in our in vitro studies. An important caveat to the use of gedunin and its derivatives as a treatment for PD is the reported modulatory activity of p23 on certain steroid receptors which could result in unwanted "off-target" effects in non-neuronal tissues which suggest that direct brain targeting may be required (Ros-Bernal et al., 2011; Reebye et al., 2012) .
In summary, these data potentially provide a novel link between two entities whose dysfunction have been independently associated with PD-associated neurodegeneration, hsp90 and PHD2-HIF1a, via interaction with the hsp90 co-factor p23 (Fig. 5 ). This could have important implications for mechanisms underlying the involvement of these pathways in PD neuropathology and suggests that dopaminergic p23 inhibition be considered as a novel therapeutic target for the disorder.
